Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study

Compass Pathways (Nasdaq: CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depression.

The company reported that it had completed psilocybin administration to all 216 patients that were targeted for Compass’ phase IIb clinical trial for treatment-resistant depression

The trial, which is using a proprietary version of isolated psilocybin known as COMP360, is …

Full story available on Benzinga.com

More Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study